OIS at AAO 2015

Aura Biosciences

Nov 12, 2015 11:25am ‐ Nov 12, 2015 11:33am


Aura Biosciences is developing a new class of therapies to target and selectively destroy tumor cells. Its lead program in ocular melanoma, developed under a CRADA with the National Cancer Institute (NCI), has been granted orphan drug status by the US Food and Drug Administration.


You must be logged in and own this session in order to post comments.